Cingulate Inc. (CING)
Market Cap | 3.20M |
Revenue (ttm) | n/a |
Net Income (ttm) | -22.50M |
Shares Out | 3.98M |
EPS (ttm) | -20.81 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 7,029 |
Open | 0.800 |
Previous Close | 0.780 |
Day's Range | 0.770 - 0.805 |
52-Week Range | 0.700 - 21.800 |
Beta | -0.89 |
Analysts | Buy |
Price Target | 8.00 (+900.0%) |
Earnings Date | May 8, 2024 |
About CING
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-21... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 900.00% from the latest price.
News
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stockholders' Equity KANSAS CITY, Kan., May 08, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), ...
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform techno...
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform techno...
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
$17.8 Million Raised Since Beginning of 2023 $9.1 Million of Debt Converted to Equity at a Premium Phase 3 ADHD Data Continues to Impress
Cingulate to Participate in Benzinga All Live Access Event
KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform techno...
Cingulate to Attend DCAT Week 2024 in New York City
Will Host Licensing Meetings with Multiple Parties to Discuss Assets, Pipeline and Technology Will Host Licensing Meetings with Multiple Parties to Discuss Assets, Pipeline and Technology
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
Announcement Follows Recent Public Offering and Successful Capital Raising Activity Announcement Follows Recent Public Offering and Successful Capital Raising Activity
Cingulate Announces Closing of $7.5 Million Public Offering
KANSAS CITY, Kan., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Ti...
Cingulate Announces Pricing of $7.5 Million Public Offering
KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Ti...
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform techno...
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery plat...
Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing
Shares of Cingulate Inc. CING, +101.52% blasted 226.3% higher in premarket trading Thursday after the biopharmaceutical company disclosed that the delisting of its stock has been delayed until at leas...
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
KANSAS CITY, Kan., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technol...
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity
Cingulate to Host CNS Key Opinion Leader Panel in New York City
Expert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations Expert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delive...
Cingulate Inc. to Present at the LD Micro Main Event XVI
KANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technol...
Cingulate Inc. To Present at the LD Micro Main Event XVI
Presentation on Wednesday, October 4th at 02:30 PM PT Kansas City, Kansas--(Newsfile Corp. - September 21, 2023) - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary ...
Cingulate Announces Closing of $4.0 Million Public Offering
KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision T...
Cingulate Announces Pricing of $4.0 Million Public Offering
KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision ...
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI-S) Scores, with Investigators Observing Trend Tow...
Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium
KANSAS CITY, Kan., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery pla...
Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research announces the first dosing in Cingulate Therapeutics' CTx-1301 Phase III laboratory classroom study.
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
KANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform techno...
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
Werth Family Investment Associates Provides Additional Capital Investment Phase 3 Adult Efficacy and Safety Trial of CTx-1301 Data Released CTx-1301 Phase 3 Pediatric and Adolescent Studies Underway
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
Announcement Confirms Cingulate on Track with Development and Regulatory Milestones Announcement Confirms Cingulate on Track with Development and Regulatory Milestones